

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

NCT06657846

Status	RECRUITING
Sponsor	Gruppo Italiano Malattie EMatologiche dell'Adulto
Enrollment	100 participants

Plain Language Summary

This study looks at quality of life and the financial burden experienced by people diagnosed with VEXAS syndrome — a rare inflammatory disease caused by a genetic mutation that affects blood cells and causes widespread inflammation. The study uses surveys to understand the real-world impact of living with this condition.

****You may be eligible if...****

- You are 18 or older
- You have a confirmed diagnosis of VEXAS syndrome (detected through a specific gene mutation called UBA1)
- You can provide written consent

****You may NOT be eligible if...****

- You have a psychiatric disorder or significant cognitive impairment
- You cannot read or understand the local language used in the study

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (2)

- Adult patients (e 18 years old) with a confirmed diagnosis of VEXAS syndrome (UBA1 pathogenic mutation detected)
- Written informed consent

Exclusion (2)

- Having any kind of psychiatric disorder or major cognitive dysfunction.
- Not able to read and understand local language

Locations (17 total)

Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia, Bergamo, Italy
Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia, Bologna, Italy
... and 14 more locations

<https://clinicaltrials.gov/study/NCT06657846>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).